Blurbs

Maxim Group Keeps Their Buy Rating on Citius Pharmaceuticals (CTXR)

In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Citius Pharmaceuticals (CTXRResearch Report), with a price target of $4.00. The company’s shares opened today at $1.22.

Okunewitch covers the Healthcare sector, focusing on stocks such as Citius Pharmaceuticals, Gilead Sciences, and Kiora Pharmaceuticals. According to TipRanks, Okunewitch has an average return of -27.1% and a 28.57% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Citius Pharmaceuticals with a $7.00 average price target.

See today’s best-performing stocks on TipRanks >>

Based on Citius Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $8.86 million. In comparison, last year the company had a GAAP net loss of $5.82 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

Read More on CTXR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More